Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study ?>

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. 2002 and July 2005 were entered into a prospective, open-label study. Despite the chronic nature of psoriasis, to date limited long-term clinical data have been available, as challenges are inherent in conducting a long-term analysis. Methods: We used data from an open-label study over 3 years of continuous treatment with infliximab in patients with plaque-type psoriasis. Infliximab for severe, treatment-resistant. Clinical assessments, including Psoriasis Area and Severity Index (PASI) and Disease Activity Score (DAS), were performed at baseline and every 2 weeks afterward. In conclusion, low-dose infliximab treatment leads to decreased neoangiogenesis and deactivation of the endothelium, resulting in decreased cell infiltration and clinical improvement in psoriasis and psoriatic arthritis. The study was a 24-week, single-centre, prospective, open-label trial. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study 2Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. In another prospective cohort study of 100 PsA patients, the majority of patients showed progression in the number of joints involved, and 68 percent manifested radiographic progression at five years 2,3. Severe disease may adversely affect survival. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Efficacy of infliximab in resistant psoriatic arthritis. PubMed journal article First experience with therapy of severe forms of psoriasis with biosimilar inflixima was found in Unbound MEDLINE. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.

In clinical studies of infliximab for active Crohn’s disease, all patients had experienced an inadequate response to prior conventional therapies, including corticosteroids, 5-aminosalicylates (5-ASA), and/or 6-mercaptupurine/ azathioprine (6-MP/AZA). These randomized controlled trials confirm the findings of an open label study of infliximab in 21 patients with active spondyloarthropathy who received a maintenance regimen of 5 mg/kg infliximab every 14 weeks, 19 of whom were followed for 1 year (Kruithof et al, 2002). A phase II clinical trial by Suhler and associates (2009) reported the 2-year follow-up data of patients with refractory uveitis treated with intravenous infliximab as part of a prospective clinical trial. Clinicians may be confronted with difficult-to-treat psoriasis cases for which there are scant data to rely upon for guidance. Ustekinumab, an inhibitor of interleukin (IL) 12 and 23, presents a unique therapeutic pathway in patients who are resistant to other therapies. Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study. The aim of this systematic review is to evaluate efficacy and safety of off-label dosing regimens (dose escalation, dose reduction, and interrupted treatment) with etanercept, adalimumab, infliximab, ustekinumab, and alefacept for psoriasis treatment. Data Sources and Study Selection We searched OVID Medline from January 1, 1990 through August 1, 2011 for prospective clinical trials that studied biologic therapy for psoriasis treatment in adults. Conclusion Dose escalation in non-responders generally resulted in increased efficacy in the examined biologics used to treat moderate-to-severe psoriasis.

Addition Of Infliximab To Standard Acute Graft-versus-host Disease Prophylaxis Following Allogeneic Peripheral Blood Cell Transplantation

A classification of psoriasis vulgaris according to phenotype 3Patients with moderate-to-severe plaque psoriasis require continuous therapy; Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis. Treatment of nail psoriasis with adalimumab: an open label unblinded study.

Remicade (infliximab)